Injectable hydrogel system prolongs joint retention in osteoarthritis

by University at Buffalo

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

Osteoarthritis is a leading cause of chronic pain and disability worldwide. Current intra-articular standards of care, such as analgesics, corticosteroids and viscosupplements, provide only transient symptomatic relief and do not reliably modify disease progression. A major translational barrier is the rapid clearance of small-molecule drugs and biologics from synovial fluid, as well as the difficulty of delivering hydrophobic compounds at therapeutic concentrations without systemic exposure.

The University at Buffalo technology is an injectable hydrogel platform that enables sustained local delivery of therapeutics for osteoarthritis. Following a single minimally invasive injection, the formulation rapidly transitions from a liquid to a lubricious semisolid depot at body temperature, enabling localized drug release over multiple weeks.

The biocompatible platform combines a polymer matrix with drug-loaded nanocarriers engineered for high loading of poorly soluble therapeutics using materials with prior regulatory acceptance to support clinical translation. Therapeutic agents are released through diffusion and matrix relaxation, providing controlled local exposure. Validated with a SIRT6 activator, the platform is readily adaptable to other hydrophobic disease-modifying agents.

Advantages:

• Extended therapeutic window: Prolonged local delivery and retention while minimizing the frequency of invasive injections and the risk of systemic side effects.
• Disease-modifying potential: Specifically designed to deliver agents that target the biological drivers of OA, including chronic inflammation and cellular senescence.
• Synergistic dual action: Serves as both a sustained-release vehicle and a viscosupplement, with potential to restore joint lubrication while treating the underlying disease.
• Broad therapeutic compatibility: Supports delivery of poorly soluble compounds in aqueous solution with high drug-loading capacity.
• Platform versatility: Adaptable to multiple joint applications and therapeutic payloads.

Applications:

• Primary indication: Knee osteoarthritis (large addressable market).
• Secondary indications: Post-traumatic OA, intervertebral disk degeneration, rotator cuff degeneration and localized delivery of hydrophobic candidates.

Key medical concepts

OsteoarthritisOsteoarthritis, Knee

Clinical categories

OrthopedicsClinical pharmacology Provided by University at Buffalo Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Injectable hydrogel system prolongs joint retention in osteoarthritis (2026, August 13) retrieved 13 August 2026 from https://medicalxpress.com/news/2026-08-hydrogel-prolongs-joint-retention-osteoarthritis.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.